🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fostering Data Sharing

Search Papers Authors Institutions Grants FAIR About

TheSindex

Fostering Data Sharing

Empowering the data sharing that empowers science — an open, citation-grounded index for datasets.

Product

Search
API
Explore
Rankings

Resources

Methodology
Data Sources
Documentation
Press

Organization

About
Team
Wikidata

© 2026 theSindex. All rights reserved.

Home
Authors
Fangxin Hong

Fangxin Hong

ORCID: 0000-0001-8049-0086

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 15 papers. Top paper: “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W”.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of Clinical Oncology(2020)10.1200/jco.19.02630

N/A

4.7DataRank · unranked

179 citations

Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30221-0

N/A

3.3DataRank · unranked

142 citations

Fangxin Hong, Richard F. Ambinder, Jonathon B. Cohen, Michael J. Robertson, Kevin A. David +12 more

Decision regret, adverse outcomes, and treatment choice in men with localized prostate cancer: Results from a multi-site randomized trial

Urologic Oncology Seminars and Original Investigations(2021)10.1016/j.urolonc.2020.11.038

N/A

1.1DataRank · unranked

21 citations

Fangxin Hong, Traci M. Blonquist, Barbara Halpenny, Niya Xiong, Christopher P. Filson +12 more

A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-1345

N/A

0.851DataRank · unranked

22 citations

Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig +11 more

Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

Cancer Discovery(2021)10.1158/2159-8290.cd-20-0913

N/A

0.809DataRank · unranked

219 citations

Erik H. Knelson, Jacquelyn O. Wolff, Amir Vajdi, Maria Saigí, Marco Campisi +38 more

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

JCO Precision Oncology(2023)10.1200/po.22.00421

N/A

0.656DataRank · unranked

16 citations

Yael Flamand, Melissa Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong +19 more

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001007

N/A

0.614DataRank · unranked

59 citations

Biagio Ricciuti, E. Jimenez-Aguilar, Fangxin Hong, Zihan Wei, Mizuki Nishino +10 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0.457DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

Increase in side effect bother was associated with early treatment discontinuation in a clinical trial among multiple myeloma patients.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19136

N/A

0.269DataRank · unranked

5 citations

Fengmin Zhao, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +9 more

SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA Genotyping

JTO Clinical and Research Reports(2021)10.1016/j.jtocrr.2021.100151

N/A

0.241DataRank · unranked

4 citations

Rubii M. Tamen, Pablo Martínez, Alicia Sable-Hunt, Tony Addario, Pete Barbour +11 more

Predictive value of bother by side effects of treatment prior to protocol therapy for early treatment discontinuation in clinical trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.e19132

N/A

0.208DataRank · unranked

3 citations

John Devin Peipert, Ju‐Whei Lee, Fangxin Hong, Edward H. Ip, Ilana F. Gareen +15 more

Exploring Chemotherapy‐Induced Peripheral Neuropathy Severity Patterns in Young Adult Women With Breast Cancer Receiving Weekly or Dose Dense Paclitaxel

European Journal of Cancer Care(2025)10.1155/ecc/4229814

N/A

0DataRank · unranked

0 citations

Emanuele Mazzola, A. Lindsay Frazier, Roy Freeman, Marilyn J. Hammer, Fangxin Hong +5 more

Racial/ethnicity differences when endorsing influential factors for prostate cancer treatment choice: An analysis of data from the personal patient profile-prostate (P3P) I and II trials.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.6_suppl.351

N/A

0DataRank · unranked

1 citations

Fangxin Hong, Barbara Halpenny, Matthew Epstein, Quoc‐Dien Trinh, Donna L. Berry

Association between allostatic load, symptom burden and mortality in E1A11 trial for myeloma.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.12102

N/A

0DataRank · unranked

0 citations

Noah Graham, Shaji Kumar, Ju‐Whei Lee, David Cella, Fengmin Zhao +9 more

Examining allostatic load, neighborhood socioeconomic status, symptom burden and mortality in multiple myeloma patients

Blood Cancer Journal(2022)10.1038/s41408-022-00648-y

N/A

0DataRank · unranked

25 citations

Noah Graham, Shaji Kumar, Ju‐Whei Lee, Susanna Jacobus, Matthias Weiss +12 more